296,836 Shares in Grifols, S.A. (NASDAQ:GRFS) Purchased by Verition Fund Management LLC

Verition Fund Management LLC bought a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 296,836 shares of the biotechnology company's stock, valued at approximately $2,636,000.

Several other hedge funds also recently modified their holdings of GRFS. GAMMA Investing LLC boosted its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 1,135 shares during the period. Signaturefd LLC boosted its stake in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 2,153 shares during the period. AQR Capital Management LLC acquired a new stake in Grifols in the 2nd quarter valued at approximately $89,000. Cetera Advisors LLC bought a new position in Grifols in the 1st quarter worth approximately $147,000. Finally, Chesapeake Capital Corp IL acquired a new position in shares of Grifols during the third quarter worth approximately $148,000.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.

Grifols Stock Down 1.5 %

Shares of NASDAQ GRFS traded down $0.11 during mid-day trading on Thursday, hitting $7.17. The company had a trading volume of 414,124 shares, compared to its average volume of 1,867,653. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The business's 50-day simple moving average is $8.67 and its 200-day simple moving average is $8.09.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.